Why Is CytomX Therapeutics Stock Falling On Wednesday?

All NewsMarch 18, 2026

CytomX stock falls after $250 million share sale, even as new colorectal cancer data shows strong response and growth potential.

Importance Rank:

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent